SEC Form 4 · accession 0001209191-18-038210
Ultragenyx Pharmaceutical Inc. · RARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Theodore Alan Huizenga
Officer — VP, Controller and PAO
Period of report
Jun 15, 2018
Accepted (ET)
Jun 15, 2018 · 7:55 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001515673
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 15, 2018 | M | 2,955 | $21.00 | A | 12,895 | D | |
| Common StockF1 | Jun 15, 2018 | S | 955 | $83.70 | D | 11,940 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $21.00 | Jun 15, 2018 | M | 2,955 | D | — | Jan 29, 2024 | Common Stock | 2,955 | 19,448 | D |
Explanation of responses
- F1Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- F21/4th of the option vested one year from January 29, 2014 and then 1/48th monthly thereafter.